Amyloid A, Serum, Human (Serum, Amyloid A, SAA) BioAssay(TM) ELISA Kit

Amyloid A, Serum, Human (Serum, Amyloid A, SAA) BioAssay(TM) ELISA Kit is to be used for the in vitro quantitative determination human serum amyloid A (SAA) concentrations in serum, plasma, cell culture supernatant and other biological fluids.\n\nAmyloidosis includes a family of diseases which have in common the extracellular deposition of beta-pleated ?brillar protein. Amyloidosis associated with chronic in?ammatory conditions. (AA-type) and Amyloidosis related to plasma cel dyscrasia (AL-type) are the most common. The frequency of amyloidosis associated with chronic hemodialysis (B2M-type) is growing rapidly.\n\nSensitivity:\nCalibrator Diluent 1: 1.1ng/ml\nCalibrator Diluent 2: 0.6ng/ml\n\nRange: 0-80ng/ml\n\nSpecificity:\nRecognizes both natural and recombinant human SAA. Does no exhibit detectable crossreactivity with human IL-8, IL-1b, MCAF, FGF, TGF-b, EGF, GM-CSF, M-CSF, MCP-3, TNF-a, RANTES and EPO.\n\nKit Components:\nA2275-60C1: SAA microtiter plate, 1 x 96wells\nA2275-60C2: SAA conjugate, 1 x 15ml\nA2275-60C3: SAA standard, 2 x 160ng\nA2275-60C4: Calibator Diluent I, 1 x 30ml\nA2275-60C5: Calibator Diluent II, 1 x 30ml\nA2275-60C6: Wash buffer (20X), 1 x 60ml\nA2275-60C7: Substrate A, 1 x 11ml\nA2275-60C8: Substrate B, 1 x 11ml\nA2275-60C9: Stop solution, H2SO4, 1 x 14ml\n\nStorage and Stability:\nStore *A2275-60C3 at -20 degrees C. Store other components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

A2275-60C

Size

96Tests

Applications

ELISA

References

US Biological application references: 1. Viguerie, N. et al., (2012) Physiol. Genomics physiolgenomics.00032.2011 2. Hergenroeder, G. et al., (2008) J. Neurotrauma 25:79-93. 1. Skinner, M., J. Internal Med. 232: 514-523 (1992). 2. Kisilevsky, R., Med. Hypoth. 35(3): 37-41 (1991). 3. Malle, E., et al., Atheroscl. 102: 131-146 (1993). 4. Baussermann, L.L., et al. Eur. J. Clin. Invest. 18: 619-626, (1988). 5. Badolato, R., et al., J. Exp. Med. 180: 203-209 (1994). 6. Xu, L., et al., J. Immunol. 155: 1184-1190 (1995). 7. Liang, J., et al., J. Lipid Res. 36: 37-46 (1995). 8. Knecth, A., et al., Ann. Int. Med. 102(1): 71-72 (1985). 9. Reinoff, J.R., et al., Mol. Bio. Med. 7: 287-298 (1990). 10. Marhaug, G., et al., Acta. Peadiatr. Scand. 72: 861-866(1983). 11. Casl, M.T., et al., Nephron. 70: 112-113 (1995). 12. Casl, M.T., et al., Ann. Clin. Biochem. 30: 272-277 (1993). 13. Husebekk, A., et al., Scand. J. Infec. Dis. 18: 389-394 (1986). 14. Nakayama, T., et al., Clin. Chem. 39(2): 293-297 (1993). 15. Honkanen, E., et al., Nephron. 57: 283-287 (1991). 16. Hiroyuki, M., et al., Arch. Dis. Child. 68: 210-214 (1993). 17. Thomson, D., et al., Ann. Clin. Biochem. 29: 123-131 (1992). 18. Luizzo, G., et al., N. Eng. J. Med. 331: 417-424 (1994). 19. Casl, M.T., et al., Ann. Clin. Biochem. 32: 196-200 (1995).